Biotech · Private company
Immunovant Sciences GmbH
Track this companyFree. Adds Immunovant Sciences GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials178 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- BatoclimabPhase 3 · Thyroid Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Batoclimab 340 mg SC bi-weeklyPhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Batoclimab 340 mg SC weeklyPhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Batoclimab 680 mg SC weeklyPhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- IMVT-1402Phase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Observational cohort studyPhase 3 · Thyroid Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- BatoclimabPhase 2 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- Batoclimab 340 mg SC weeklyPhase 2 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- Batoclimab 680 milligrams (mg) subcutaneous (SC) weeklyPhase 2 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- ImeroprubartPhase 2 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
- IMVT-1402Phase 2 · Graves' DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IMVT-1402Phase 2 · Primary Sjögren's SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- IMVT-1402Phase 2 · Rheumatoid ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- IMVT-1402Phase 2 · Subacute Cutaneous Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- RVT-1401Phase 2 · Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- RVT-1401 (Administered via subcutaneous injection)Phase 2 · Graves' Ophthalmopathy (GO)ClinicalTrials.gov · fetched Nov 12, 2026
- RVT-1401 340 mg/weeklyPhase 2 · Warm Autoimmune Hemolytic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
- RVT-1401 680 mg/weeklyPhase 2 · Warm Autoimmune Hemolytic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials17
- A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)PHASE2 · ENROLLING_BY_INVITATION · started Jan 26, 2026ClinicalTrials.gov NCT07286006 · fetched Nov 12, 2026
- An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PHASE2 · TERMINATED · started Aug 28, 2025ClinicalTrials.gov NCT07188844 · fetched Nov 12, 2026
- Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease ActivityPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 30, 2025ClinicalTrials.gov NCT06979531 · fetched Nov 12, 2026
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseasePHASE2 · RECRUITING · started Jun 19, 2025ClinicalTrials.gov NCT07018323 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisPHASE3 · RECRUITING · started May 27, 2025ClinicalTrials.gov NCT07039916 · fetched Nov 12, 2026
- Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PHASE2 · RECRUITING · started Mar 18, 2025ClinicalTrials.gov NCT07032662 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 19, 2025ClinicalTrials.gov NCT06980805 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 10, 2025ClinicalTrials.gov NCT06754462 · fetched Nov 12, 2026
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseasePHASE2 · RECRUITING · started Dec 17, 2024ClinicalTrials.gov NCT06727604 · fetched Nov 12, 2026
- Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseasePHASE3 · COMPLETED · started Jan 5, 2023ClinicalTrials.gov NCT05524571 · fetched Nov 12, 2026
- To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDPPHASE2 · TERMINATED · started Dec 15, 2022ClinicalTrials.gov NCT05581199 · fetched Nov 12, 2026
- Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseasePHASE3 · COMPLETED · started Nov 23, 2022ClinicalTrials.gov NCT05517421 · fetched Nov 12, 2026
- Extension Study to Assess Batoclimab in Participants With Thyroid Eye DiseasePHASE3 · TERMINATED · started Nov 6, 2022ClinicalTrials.gov NCT05517447 · fetched Nov 12, 2026
- Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia GravisPHASE3 · TERMINATED · started Jun 27, 2022ClinicalTrials.gov NCT05403541 · fetched Nov 12, 2026
- To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).PHASE2 · TERMINATED · started Aug 11, 2020ClinicalTrials.gov NCT04253236 · fetched Nov 12, 2026
- ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )PHASE2 · TERMINATED · started Jul 23, 2019ClinicalTrials.gov NCT03938545 · fetched Nov 12, 2026
- A Study of RVT-1401 in Myasthenia Gravis (MG) PatientsPHASE2 · COMPLETED · started May 21, 2019ClinicalTrials.gov NCT03863080 · fetched Nov 12, 2026